Background: Chronic Myeloid Leukaemia (CML) starts in certain blood-forming cells of the bone
marrow when cells acquire Philadelphia chromosome. Nowadays, scientists attempt to find novel and safe
therapeutic agents and approaches for CML therapy using Tyrosine Kinase Inhibitors (TKIs), CML
conventional treatment agents, has some restrictions and also adverse effects. Recently, it has been proposed that
phytochemicals, such as flavonoids due to their low side effects and notable safety have the potential to be used
for CML therapy.
Materials and Methods: K-562 cells were exposed with three concentrations of the querectin (10, 40 and
80µM) for 12, 24 and 48 hours. After that, these cells apoptosis rate was estimated using Annexin-V/PI staining
and flowcytometry analysis, and their proliferation rate was evaluated using 3-[4,5-dimethylthiazol-2-yl]-2,5
diphenyl tetrazolium bromide (MTT). Finally, the expression of the 70 and 90 kilodalton heat shock proteins
(HSP70 and 90), methionine adenosyltransferase 2A (MAT2A), Forkhead box protein M1 (FOXM1), caspase-3
and -8, Bcl-X(L) and Bax involved in leukemic cells survival and proliferation was assessed using Real-Time
PCR within 12, 24 and 48 hours after exposure with quercetin 40 and 80µM.
Results: Considering consequences, querecetin induced apoptosis in K-562 cells, and also abrogated these cells
proliferation. On the other hand, RT-PCR results showed a reduction in some of the candidate genes expression,
especially HSP70, Bcl-X(L) and FOXM1, when cells were treated with quercetin 40 and 80µM. Also, Bax,
caspase-3 and caspase-8 expression was significantly improved in K-562 cells upon quercetin exposure.
Conclusion: We concluded that CML therapy by querecetin due to its anti-proliferative and anti-survival
potentials could lead to the promising therapeutic outcome through targeting major survival and proliferation
involved genes expression.